Table 6. Outcomes in active and placebo groups in the North compared to the South arm.
IQR = Interquartile range
| Characteristic | South Active N=106 Male (n=76) Female (n=30) (sc. 3/4 = 5) (sc. 5 = 43) (sc. 6 = 58) | North Active N=317 Male (n=184) Female (n=133) (sc. 3/4 = 7) (sc. 5 = 93) (sc. 6 = 217) | South Placebo N=27 Male (n=22) Female (n=5) (sc. 3/4 = 1) (sc. 5 = 13) (sc. 6 = 13) | North Placebo N=328 Male (n=182) Female (n=146) (sc. 3/4 = 13) (sc. 5 = 103) (sc. 6 = 212) | Active between regions (P-value) | Placebo between regions (P-value) |
| Day 14 WHO COVID-19 Clinical Score – median (IQR) | 1 (1-2) | 1 (1-2) | 4 (2-8) | 7 (2-8) | 0.81 | 0.27 |
| Day 18 WHO COVID-19 Clinical Score – median (IQR) | 1 (1-1) | 1 (1-1) | 2 (1-8) | 7 (2-8) | 0.60 | 0.23 |
| Recovery rate over 14 days, no. (%) | 85 (80.2%) | 258 (81.4%) | 13 (48.1%) | 117 (35.7%) | 0.79 | 0.16 |
| Females | 24 (80.0%) | 109 (82.0%) | 1 (20.0%) | 51 (34.9%) | 0.81 | 0.54 |
| Males | 63 (82.9%) | 149 (81.0%) | 9 (40.9%) | 66 (36.3%) | 0.71 | 0.66 |
| Baseline Scores 3 and 4 | 3 (60.0%) | 7 (100.0%) | 1 (100%) | 11 (84.6%) | 0.16 | 0.16 |
| Baseline Score 5 | 41 (95.3%) | 82 (88.2%) | 9 (69.2%) | 51 (49.5%) | 0.12 | 0.11 |
| Baseline Score 6 | 41 (70.7%) | 169 (77.9%) | 3 (23.1%) | 55 (25.9%) | 0.27 | 0.82 |
| Recovery rate over 28 days no. (%) | 93 (87.7%) | 271 (85.5%) | 14 (51.8%) | 155 (47.3%) | 0.55 | 0.63 |
| Females | 27 (90.0%) | 117 (88.0%) | 2 (40.0%) | 71 (48.6%) | 0.74 | 0.72 |
| Males | 68 (89.5%) | 154 (83.7%) | 14 (63.6%) | 84 (46.2%) | 0.19 | 0.074 |
| Baseline Scores 3 and 4 | 4 (80.0%) | 7 (100.0%) | 1 (100%) | 11 (84.6%) | 0.32 | 0.16 |
| Baseline Score 5 | 43 (100.0%) | 86 (92.5%) | 9 (69.2%) | 66 (64.1%) | 0.008 | 0.39 |
| Baseline Score 6 | 47 (81.0%) | 178 (82.0%) | 4 (30.8%) | 78 (36.8%) | 0.81 | 0.67 |
| All-cause mortality rate over 14 days, no. (%) | 7 (6.6%) | 27 (8.5%) | 8 (29.6%) | 130 (39.6%) | 0.68 | 0.34 |
| Females | 0 (0.0%) | 11 (8.3%) | 2 (40.0%) | 53 (36.3%) | 0.22 | 1.00 |
| Males | 7 (9.2%) | 16 (8.7%) | 6 (27.3%) | 77 (42.3%) | 1.00 | 0.52 |
| Baseline Scores 3 and 4 | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (7.7%) | 1.00 | 1.00 |
| Baseline Score 5 | 1 (2.3%) | 4 (4.3%) | 2 (15.4%) | 31 (30.1%) | 1.00 | 0.34 |
| Baseline Score 6 | 6 (10.3%) | 23 (10.6%) | 6 (46.2%) | 98 (46.2%) | 1.00 | 1.00 |
| All-cause mortality rate over 28 days, no. (%) | 10 (9.4%) | 35 (11.0%) | 9 (33.3%) | 162 (49.4%) | 0.72 | 0.11 |
| Females | 2 (6.7%) | 12 (9.0%) | 2 (40.0%) | 71 (48.6%) | 1.00 | 1.00 |
| Males | 8 (10.5%) | 23 (12.5%) | 7 (31.8%) | 91 (50.0%) | 0.83 | 0.12 |
| Baseline Scores 3 and 4 | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 2 (15.4%) | 1.00 | 1.00 |
| Baseline Score 5 | 1 (2.3%) | 5 (5.4%) | 2 (15.4%) | 37 (35.9%) | 0.66 | 0.21 |
| Baseline Score 6 | 9 (15.5%) | 30 (13.8%) | 7 (53.8%) | 123 (58.0%) | 0.83 | 0.78 |
| Median hospitalization days (IQR) | 8 (5-10) | 8 (6-13) | 14 (12-18) | 12 (8-18) | 0.07 | 0.12 |
| Post-randomization to alive hospital discharge, median days (IQR) | 5 (3-8) | 5 (3-8) | 12 (9-16) | 10 (6-14) | 1.00 | 0.025 |